Ajinomoto (2802.T) traded up 0.36 % during a 24 hours period ending at 03:42 PM Central Europe on Monday 26th. One Ajinomoto stock can currently be bought for about JPY 5,013 on popular exchanges. Current supply of Ajinomoto stocks is 953.8 mn. Ajinomoto has a current market capitalization of JPY 4.8 trillions and approximately JPY 19 bn worth of Ajinomoto was traded on exchanges in the last 24 hours. Since last month end, Ajinomoto has traded 1.32 % up. Simple moving average of last 200 days is at JPY 4,859.21. The highest price of past 52 weeks was recorded at JPY 6,340 on 07/06/2026. 52 weeks low was at JPY 3,270 on 01/08/2026.

Here is how related stocks have performed in the past 24 hours:

  • Bridgestone (5108.T) traded down -0.23 % and now trades at JPY 4,037. Current market capitalisation for Bridgestone is JPY 5 trillions. Current price/earnings ratio for Bridgestone is 12.58.

  • Renesas Electronics (6723.T) traded down -1.11 % and now trades at JPY 2,783.5. Current market capitalisation for Renesas Electronics is JPY 5.3 trillions. Current price/earnings ratio for Renesas Electronics is 15.27.

  • Oriental Land (4661.T) traded up 0.03 % and now trades at JPY 3,275. Current market capitalisation for Oriental Land is JPY 5.4 trillions. Current price/earnings ratio for Oriental Land is 39.61.

  • Daiichi Sankyo (4568.T) traded down -0.67 % and now trades at JPY 2,825. Current market capitalisation for Daiichi Sankyo is JPY 5.1 trillions. Daiichi Sankyo has a current price to earnings ratio of 21.31. AstraZeneca’s recent Phase III studies have reported clinically meaningful benefit in targeted cancer therapies. In gastric and gastro‑esophageal junction cancer, the antibody‑drug conjugate Sone‑Ve demonstrated a substantial improvement in overall survival compared with investigator‑chosen regimens, with consistent benefits across patient subgroups defined by CLDN18.2 expression. The safety profile was manageable, with no new adverse events identified. In non‑small‑cell lung cancer, the combination of TAGRISSO and savolitinib showed a notable reduction in disease progression and mortality in patients whose tumors overexpressed or amplified MET after prior TAGRISSO treatment. The trial also indicated an extension in overall survival and a higher proportion of patients alive at one year relative to standard chemotherapy. These results reinforce AstraZeneca’s strategy of combining targeted agents to address resistance mechanisms in advanced solid tumours.

  • Seven & I (3382.T) traded up 0.02 % and now trades at JPY 2,136.5. Seven & I has a market capitalisation of JPY 4.8 trillions. Current price/earnings ratio for Seven & I is 16.76.

About Ajinomoto

Ajinomoto Co., Inc. is a consumer staples company based in Japan that specializes in producing and selling a diverse range of food products such as seasonings, edible oils, processed foods, beverages, and dairy products. Additionally, the company develops and manufactures pharmaceuticals, amino acids, and specialty chemicals. You can find more information about their offerings and initiatives on their website, www.ajinomoto.co.jp , and they are listed on the Tokyo Stock Exchange. Their initial public offering took place on May 1, 1949.